Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8447)	1/23/1999 2:27:00 AM
From: aknahow	Respond to of 17367

From Yahoo in case someone does not see it. Hello Conpelo by: PrometheusTex 4821 of 4821 I can certainly appreciate your choice to disagree. As you know, mortality in aggressively treated menin. cases has dropped dramatically over the last decades. Some believe even a number of 20% may be high. I, however, was not referring to the published information in the Phase 2 trial, but rather to that which was not published: when rBPI was administered to children with "dead" blue extremities due to DIC, they reperfused... they turned pink again. Clearly, if rBPI is bringing kids back from the brink, there will be some limbs too far gone to prevent amputation even if they are partially reperfused... but name another drug that could be given that visibly reverses DIC in septic shock. This, I was told, was the dramatically visible effect that let the doctors instantly know who was on bpi and who was placebo. I agree with you that reperfusion would be a tough endpoint; it is not the one that will get this drug approved. More to your point, I have been told now that the bureau of biologics traditionally looks only at mortality as an endpoint... since I was under the impression that morbidity was also being tracked, I will have to do more research/questioning and try to revise my opinion appropriately. thanks, ProTex